- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04178174
Amplification stéréotaxique et radiothérapie de courte durée pour le cancer de l'oropharynx (SHORT-OPC)
Amplification stéréotaxique et radiothérapie de courte durée pour l'essai sur le cancer de l'oropharynx associé au VPH : un essai randomisé multicentrique de phase II
This is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation.
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
Concurrent platinum-based chemoradiation remains the standard of care in locally advanced head and neck cancer. The current standard radiation regimen consists in a 7-week course of conventionally fractionated radiotherapy to the gross tumor volume (GTV), along with bilateral prophylactic neck irradiation to an elective dose of ~ 50 Gy in 2 Gy per fraction. In addition to being cumbersome, the current protracted daily radiation course is associated with high rates of acute and late toxicities and significant deterioration of patients' quality of life. In the light of the remarkably improved prognosis of the distinct subgroup of HPV-OPC, there is growing interest for treatment de-intensification strategies in contemporaneous OPC cohorts.
Stereotactic ablative radiotherapy (SABR) allows for ultra-precise delivery of ablative radiation dose over a small number of fractions, by combining sharp dose gradients with use of optimal image guidance. The increased conformity and reduced margins used in SABR can substantially reduce the dose to surrounding organs at risk and could therefore reduce toxicity. In addition, previous work has shown that an elective dose of 40 Gy in 2 Gy per fraction, in conjunction with chemotherapy, is sufficient for microscopic sterilisation of cancer cells and can translate into a reduction of toxicities.
The goal of this trial is to compare the efficacy and safety of short-course chemoradiation consisting in stereotactic boost to the gross tumor of 14 Gy in 2 fractions followed by de-esclalated chemoradiation (40 Gy in 20 fractions and concurrent 2 cycles of Cisplatin 100mg/m2) in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation (70 Gy in 33 fractions with 2-3 cycles of Cisplatin 100mg/m2).
This is an open label randomized phase III non inferiority trial. Patients will be randomized using a 1:1 ratio between the standard and the experimental arm and will be stratified by tumor stage and use of concurrent chemotherapy.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Diane Trudel
- Numéro de téléphone: 514-890-8254
- E-mail: diane.dt.chum@ssss.gouv.qc.ca
Lieux d'étude
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 5L3
- Recrutement
- BC Cancer - Kelowna
-
Contact:
- Jennifer Petterson
- Numéro de téléphone: 250-717-4272
- E-mail: jennifer.petterson@bccancer.bc.ca
-
-
Ontario
-
London, Ontario, Canada
- Recrutement
- London Health Sciences Center
-
Contact:
- Karen Eddy
- Numéro de téléphone: (519) 685-8500
- E-mail: Karen.Eddy@lhsc.on.ca
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 1R6
- Recrutement
- Centre Hospitalier de l'Université de Montréal
-
Contact:
- Mom Phat
- Numéro de téléphone: 26906 514-890-8000
- E-mail: mom.phat.chum@ssss.gouv.qc.ca
-
Chercheur principal:
- Houda Bahig
-
Sous-enquêteur:
- Phuc-Félix Nguyen-Tan
-
-
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Recrutement
- University of Texas MD Anderson Cancer Center
-
Contact:
- Troy Sneed
- Numéro de téléphone: (713) 794-5472
- E-mail: TSneed@mdanderson.org
-
Chercheur principal:
- Jack Phan, MD PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥18 years
- Ability to provide written informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Biopsy proven diagnosis of squamous cell carcinoma of the oropharynx.
- Positive for HPV by p16 immunohistochemistry (IHC) or HPV in-situ hybridization (ISH)
- Clinical stage T1-3, N1 M0 (Stage I-II) as per AJCC 8th edition.
- Primary tumor < 30 cc
- Planned for curative chemoradiation
- For females of child-bearing age, a negative pregnancy test
Exclusion Criteria:
- Clinical N3 classification, as per AJCC 8th edition
- Clinically overt extranodal extension (ENE). As per AJCC 8th edition, clinically overt ENE is defined as invasion of the skin, infiltration of musculature/fixation to adjacent structures on clinical examination, cranial nerve, brachial plexus, sympathetic trunk or phrenic nerve invasion with dysfunction).
- Previous irradiation of the head and neck region
- Previous surgery of the HNC region (except for incisional or excisional biopsies)
- Pregnancy or breastfeeding
- Connective tissue disease
- Any medical condition that could, in the opinion of the investigator, prevent follow-up after radiotherapy.
- Non-Cisplatin concurrent chemotherapy
- Prior induction chemotherapy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: SABR boost and de-escalated chemoradiation
SABR boost of 14 Gy in 2 fractions to the GTV, immediately followed by de-escalated chemoradiation. De-escalated chemoradiation will consist in 40 Gy in 20 fractions with concurrent high dose Cisplatin (3-weekly, 100 mg/m2) for 2 cycles, aiming for a cumulative dose of 200 mg/m2. |
Stereotactic body radiotherapy boost to the gross tumor volume to a dose of 14 Gy in 2 fractions, followed by cisplatin-based chemoradiation to a dose of 40 Gy in 20 fractions |
|
Comparateur actif: Standard chemoradiation
The standard arm will consist of conventionally radiation to a dose of 70 Gy in 33 fractions concurrently with high dose Cisplatin (3-weekly, 100 mg/m2) for 2-3 cycles, aiming for a cumulative dose of ≥ 200 mg/m2. |
Standard Cisplatin-based chemoradiation to a dose of 70 Gy in 33 fractions |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression free survival
Délai: 2 years after the end of chemoradiation
|
Patient alive with no local, regional or distant recurrence at 2 years after the end of chemoradiation |
2 years after the end of chemoradiation
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Subacute toxicity
Délai: Between 2 and 6 months after the end of chemoradiation
|
Rate of grade ≥ 3 subacute toxicity |
Between 2 and 6 months after the end of chemoradiation
|
|
Acute toxicity
Délai: Less than 2 months after the end of chemoradiation
|
Rate of grade ≥ 3 acute toxicity |
Less than 2 months after the end of chemoradiation
|
|
Late toxicity
Délai: Between 6 months and 5-years after the end of chemoradiation
|
Rate of grade ≥ 3 late toxicity |
Between 6 months and 5-years after the end of chemoradiation
|
|
OS
Délai: At 2- and 5-years after the end of chemoradiation
|
Overall survival |
At 2- and 5-years after the end of chemoradiation
|
|
locoregional control
Délai: At 2- and 5-years after the end of chemoradiation
|
Patient alive with locoregional control |
At 2- and 5-years after the end of chemoradiation
|
|
Head and neck symptom burden
Délai: At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation
|
Patient-reported head and neck symptom burden as measured by the MD Anderson Symptom Inventory Head and Neck Cancer Module. The core and head and neck cancer specific symptoms are rated on a 0-10 scale to indicate the presence and severity of the symptoms. Lower scores represent better functioning and quality of life. |
At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation
|
|
Dysphagia
Délai: At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation
|
Patient-reported dysphagia as measured by the MD Anderson Dysphagia Index. Overall score ranges from 0 to 100, with higher score representing better functioning and quality of life. |
At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation
|
|
Time from treatment start to return to work
Délai: Measured in days and reported at 2-years post-treatment
|
Time from first day of treatment start to first day of return to work. |
Measured in days and reported at 2-years post-treatment
|
Collaborateurs et enquêteurs
Collaborateurs
Les enquêteurs
- Chaise d'étude: Phuc-Felix Nguyen-Tan, MD, Centre hospitalier de l'Université de Montréal (CHUM)
- Chercheur principal: Jack Phan, MD PhD, M.D. Anderson Cancer Center
- Chercheur principal: Khalil Sultanem, MD, Montreal Jewish General Hospital
- Chaise d'étude: Houda Bahig, MD PhD, Centre hospitalier de l'Université de Montréal (CHUM)
- Chercheur principal: David Palma, MD PhD, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SHORT-OPC
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .